close

NuVasive, Inc., a medical device company, engages in the design, development, and marketing of products for the surgical treatment of spine disorders. Its products are used in applications for spine fusion surgery. The company's products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines four categories of product offerings, including NeuroVision, a proprietary software-driven nerve avoidance system; MaXcess, a split-blade design retraction system providing enhanced surgical access to the spine; Biologics, which includes FormaGraft and Osteocel line of products; and specialized implants, such as SpheRx pedicle screw system, and CoRoent suite of implants, a titanium surgical mesh system with a line of precision-machined cervical and lumbar allograft implants, and related instrumentation. NuVasive also offers a range of bone allograft in patented saline packaging and spine implants, such as rods, plates, and screws, as well as Osteocel, a bone matrix product that offers three properties related to autograft, including osteoconduction, osteoinduction, and osteogenesis. The company's motion preservation products include lateral total disc replacement (TDR). It sells its products through independent sales agencies and direct sales representatives primarily in the United States. The company was founded in 1997 and is headquartered in San Diego, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	15.52
Volume	524641
Volume Avg	798603
52 Week High	34.91
52 Week Low	11.02
PE	N/A
PE (group average)	39
EPS Year	-1.73
EPS change Q/Q	-96.18%
EPS change Q/Q Yr ago	100%
EPS change Q/Q next Q est	-73.91%
EPS change Y/Y	-85.64%
REV change Q/Q	-3.71%
REV change Q/Q Yr ago	14.12%
EPS next Q est	0.23
EPS next Y est	1.05
Divident Annual	0.00
Dividend Yield	0%